Alnylam Secures Expanded Approval for Heart Drug, Paving the Way for Competition with Pfizer

In a significant development within the pharmaceutical industry, Alnylam Pharmaceuticals has received an expanded approval for its heart disease treatment, a move that positions the company squarely in competition with industry giant Pfizer. This latest FDA endorsement is expected to have profound implications for both companies and the market at large, particularly as the demand for innovative cardiovascular therapies continues to rise.

Continue reading